258 related articles for article (PubMed ID: 28405473)
1. Patient-reported outcomes from a phase III study of baricitinib in patients with conventional synthetic DMARD-refractory rheumatoid arthritis.
Emery P; Blanco R; Maldonado Cocco J; Chen YC; Gaich CL; DeLozier AM; de Bono S; Liu J; Rooney T; Chang CH; Dougados M
RMD Open; 2017; 3(1):e000410. PubMed ID: 28405473
[TBL] [Abstract][Full Text] [Related]
2. Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study.
Keystone EC; Taylor PC; Tanaka Y; Gaich C; DeLozier AM; Dudek A; Zamora JV; Cobos JAC; Rooney T; Bono S; Arora V; Linetzky B; Weinblatt ME
Ann Rheum Dis; 2017 Nov; 76(11):1853-1861. PubMed ID: 28798049
[TBL] [Abstract][Full Text] [Related]
3. Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON).
Smolen JS; Kremer JM; Gaich CL; DeLozier AM; Schlichting DE; Xie L; Stoykov I; Rooney T; Bird P; Sánchez Bursón JM; Genovese MC; Combe B
Ann Rheum Dis; 2017 Apr; 76(4):694-700. PubMed ID: 27799159
[TBL] [Abstract][Full Text] [Related]
4. Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment.
Schiff M; Takeuchi T; Fleischmann R; Gaich CL; DeLozier AM; Schlichting D; Kuo WL; Won JE; Carmack T; Rooney T; Durez P; Shaikh S; Hidalgo RP; van Vollenhoven R; Zerbini CAF
Arthritis Res Ther; 2017 Sep; 19(1):208. PubMed ID: 28923098
[TBL] [Abstract][Full Text] [Related]
5. Patient-reported outcomes from a randomized, double-blind, placebo controlled, phase III study of baricitinib
Yang Y; Xu J; Xu J; Li X; Hu J; Li X; Zhang X; He D; Bao C; Li Z; Wang G; Zerbini CAF; Spindler AJ; Kannowski CL; Wu H; Ji F; Zhan L; Liu M; Li Z
Ther Adv Musculoskelet Dis; 2021; 13():1759720X211006964. PubMed ID: 33959198
[TBL] [Abstract][Full Text] [Related]
6. Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial.
Bergman M; Tundia N; Martin N; Suboticki JL; Patel J; Goldschmidt D; Song Y; Wright GC
Arthritis Res Ther; 2022 Jun; 24(1):155. PubMed ID: 35751108
[TBL] [Abstract][Full Text] [Related]
7. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study.
Dougados M; van der Heijde D; Chen YC; Greenwald M; Drescher E; Liu J; Beattie S; Witt S; de la Torre I; Gaich C; Rooney T; Schlichting D; de Bono S; Emery P
Ann Rheum Dis; 2017 Jan; 76(1):88-95. PubMed ID: 27689735
[TBL] [Abstract][Full Text] [Related]
8. Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT.
Strand V; Pope J; Tundia N; Friedman A; Camp HS; Pangan A; Ganguli A; Fuldeore M; Goldschmidt D; Schiff M
Arthritis Res Ther; 2019 Dec; 21(1):272. PubMed ID: 31815649
[TBL] [Abstract][Full Text] [Related]
9. Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis.
Strand V; Gossec L; Proudfoot CWJ; Chen CI; Reaney M; Guillonneau S; Kimura T; van Adelsberg J; Lin Y; Mangan EK; van Hoogstraten H; Burmester GR
Arthritis Res Ther; 2018 Jun; 20(1):129. PubMed ID: 29921318
[TBL] [Abstract][Full Text] [Related]
10. Tofacitinib in Combination With Conventional Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: Patient-Reported Outcomes From a Phase III Randomized Controlled Trial.
Strand V; Kremer JM; Gruben D; Krishnaswami S; Zwillich SH; Wallenstein GV
Arthritis Care Res (Hoboken); 2017 Apr; 69(4):592-598. PubMed ID: 27565000
[TBL] [Abstract][Full Text] [Related]
11. Associations between Patient Global Assessment scores and pain, physical function, and fatigue in rheumatoid arthritis: a post hoc analysis of data from phase 3 trials of tofacitinib.
Strand V; Kaine J; Alten R; Wallenstein G; Diehl A; Shi H; Germino R; Murray CW
Arthritis Res Ther; 2020 Oct; 22(1):243. PubMed ID: 33059710
[TBL] [Abstract][Full Text] [Related]
12. Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs.
Strand V; Kremer J; Wallenstein G; Kanik KS; Connell C; Gruben D; Zwillich SH; Fleischmann R
Arthritis Res Ther; 2015 Nov; 17():307. PubMed ID: 26530039
[TBL] [Abstract][Full Text] [Related]
13. Upadacitinib improves patient-reported outcomes vs placebo or adalimumab in patients with rheumatoid arthritis: results from SELECT-COMPARE.
Strand V; Tundia N; Bergman M; Ostor A; Durez P; Song IH; Enejosa J; Schlacher C; Song Y; Fleischmann R
Rheumatology (Oxford); 2021 Dec; 60(12):5583-5594. PubMed ID: 33590829
[TBL] [Abstract][Full Text] [Related]
14. Use of daily electronic patient-reported outcome (PRO) diaries in randomized controlled trials for rheumatoid arthritis: rationale and implementation.
Bingham CO; Gaich CL; DeLozier AM; Engstrom KD; Naegeli AN; de Bono S; Banerjee P; Taylor PC
Trials; 2019 Mar; 20(1):182. PubMed ID: 30902094
[TBL] [Abstract][Full Text] [Related]
15. Baricitinib in patients with rheumatoid arthritis with inadequate response to methotrexate: results from a phase 3 study.
Li Z; Hu J; Bao C; Li X; Li X; Xu J; Spindler AJ; Zhang X; Xu J; He D; Li Z; Wang G; Yang Y; Wu H; Ji F; Tao H; Zhan L; Bai F; Rooney TP; Zerbini CAF
Clin Exp Rheumatol; 2020; 38(4):732-741. PubMed ID: 32452344
[TBL] [Abstract][Full Text] [Related]
16. Maintenance of Patient-Reported Outcomes in Baricitinib-Treated Patients with Moderate-to-Severe Active Rheumatoid Arthritis: Post Hoc Analyses from Two Phase 3 Trials.
Sholter D; Wu J; Jia B; Zhang H; Griffing K; Birt J; Reis PJS; Liu H; Bingham CO
Rheumatol Ther; 2022 Apr; 9(2):541-553. PubMed ID: 34990002
[TBL] [Abstract][Full Text] [Related]
17. Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs.
Strand V; Schiff M; Tundia N; Friedman A; Meerwein S; Pangan A; Ganguli A; Fuldeore M; Song Y; Pope J
Arthritis Res Ther; 2019 Dec; 21(1):263. PubMed ID: 31791386
[TBL] [Abstract][Full Text] [Related]
18. Sarilumab improves patient-reported outcomes in rheumatoid arthritis patients with inadequate response/intolerance to tumour necrosis factor inhibitors.
Strand V; Reaney M; Chen CI; Proudfoot CW; Guillonneau S; Bauer D; Mangan E; Graham NM; van Hoogstraten H; Lin Y; Pacheco-Tena C; Fleischmann R
RMD Open; 2017; 3(1):e000416. PubMed ID: 28326189
[TBL] [Abstract][Full Text] [Related]
19. Rapid Onset of Efficacy of Baricitinib in Chinese Patients with Moderate to Severe Rheumatoid Arthritis: Results from Study RA-BALANCE.
Li ZG; Hu JK; Li XP; Yang Y; Li XF; Xu JH; Zhang X; Xu J; Bao CD; He DY; Li ZJ; Wang GC; Zuo XX; Liu Y; Xiao ZY; Chen JW; Xin XF; Li JY; Jiang LD; Liu MR; Ji F; Li CG
Adv Ther; 2021 Jan; 38(1):772-781. PubMed ID: 33237533
[TBL] [Abstract][Full Text] [Related]
20. Relative Impact of Pain and Fatigue on Work Productivity in Patients with Rheumatoid Arthritis from the RA-BEAM Baricitinib Trial.
Michaud K; Pope JE; Emery P; Zhu B; Gaich CL; DeLozier AM; Zhang X; Dickson CL; Smolen JS
Rheumatol Ther; 2019 Sep; 6(3):409-419. PubMed ID: 31228100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
